Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable...

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeysoโ„ข (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeysoโ„ข (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma...

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Duality Biotherapeutics' partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical...

Innovent Announces Approval from China's NMPA for Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist, for Chronic Weight Management

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major...

enGeneโ€™s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Holdings Inc. a clinical-stage, non-viral gene-based immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also...

Boehringer Ingelheim and the Lung Cancer Research Foundation Announce New Research Collaboration

The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new Team Science Award and an Early Career...

Dr. Behzad Mahdavi Has Been Appointed Executive Chairman of Biodextris to Lead Its Global Commercial Expansion

Biodextris, a leading Contract Development and Manufacturing Organization (CDMO) rooted in the legacy of GSK's biologics and vaccine operations and backed by the healthcare-focused private equity firm ArchiMed, is proud to announce the appointment...

Samsung Bioepis and Organonโ€™s HADLIMAโ„ข Gains FDA Interchangeability Designation, Expanding Access to Adalimumab Alternative

Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration (FDA) has designated the HADLIMAโ„ข (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration...

Otulfiยฎ (ustekinumab-aauz) by Fresenius Kabi Now FDA-Approved as an Interchangeable Biosimilar

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfiยฎ (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelaraยฎ (ustekinumab)....

Kimeraยฎ Labs named a semifinalist in the $101 million XPRIZE Healthspan competition for pioneering innovations in healthy aging

Kimera Labs, Inc., the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in...

Rein Therapeutics announces the initiation of the RENEW Phase 2 trial of LTI-03 in patients with IPF

Rein Therapeutics a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset,...

At DDWโ€™25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity

NImmune Biopharma a private late-stage precision inflammation and immunology (โ€œI&Iโ€) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present...

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...

Serge Messerlian Appointed CEO of Creyon Bio, Leveraging Decades of Experience in Company Building and Strategic Collaborations

Creyon Bio, Inc. announced the appointment of industry leader, Serge Messerlian as Chief Executive Officer, effective immediately. Mr. Messerlian brings Creyon Bio a track record in both multinational pharmaceutical and biotechnology leadership as...

VCU Collaboration Launched by Galmed Pharmaceuticals to Address Drug Resistance in GI Cancers

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company, announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal...

Chime Biologics Partners with Polpharma Biologics to Advance Global Biosimilar Development

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, is pleased to announce a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and manufacture of a biosimilar product...

Daicel Arbor Biosciences and Element Biosciences announce a new grant opportunity, accelerating agrigenomics

Daicel Arbor Biosciences, a company that offers tools and services to accelerate genomics and synthetic biology research, in collaboration with Element Biosciences, a life sciences company democratizing access to advanced biological tools, is...

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Hanmi...

Pint Pharma secures ANVISA approval for BESREMiยฎ to treat Polycythemia Vera

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMiยฎ (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...

Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial Reported by Blue Earth Therapeutics

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and pharmacokinetic data from the 13 metastatic castrate...

Results 41 - 60 of 84